Free Trial

Diaceutics (DXRX) Competitors

Diaceutics logo
GBX 137.50 0.00 (0.00%)
As of 12:30 PM Eastern

DXRX vs. AGL, YGEN, ABDX, PRM, GDR, GENI, VRCI, DMTR, LLAI, and LLA

Should you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Verici Dx (VRCI), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). These companies are all part of the "diagnostics & research" industry.

Diaceutics vs. Its Competitors

Diaceutics (LON:DXRX) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company Overall Sentiment
Diaceutics Neutral
ANGLE Neutral

Diaceutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Diaceutics has higher revenue and earnings than ANGLE. Diaceutics is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£26.08M4.45-£2.84M-£3.37-40.78
ANGLE£2.44M6.73-£21.76M-£6.76-0.75

52.4% of Diaceutics shares are held by institutional investors. Comparatively, 18.8% of ANGLE shares are held by institutional investors. 34.3% of Diaceutics shares are held by insiders. Comparatively, 16.2% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Diaceutics presently has a consensus target price of GBX 175, indicating a potential upside of 27.27%. ANGLE has a consensus target price of GBX 40, indicating a potential upside of 684.31%. Given ANGLE's higher probable upside, analysts clearly believe ANGLE is more favorable than Diaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Diaceutics has a net margin of -10.90% compared to ANGLE's net margin of -890.91%. Diaceutics' return on equity of -7.15% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-10.90% -7.15% -6.06%
ANGLE -890.91%-76.01%-29.89%

Summary

Diaceutics beats ANGLE on 10 of the 13 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXRX vs. The Competition

MetricDiaceuticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£116.04M£892.19M£5.44B£3.07B
Dividend YieldN/A5.44%4.61%5.03%
P/E Ratio-40.782.1329.75170.63
Price / Sales4.45473.35449.48303,754.90
Price / Cash3.1211.4236.4227.96
Price / Book3.002.738.184.52
Net Income-£2.84M£334.07B£3.26B£5.90B
7 Day Performance3.56%-1.95%1.15%1.25%
1 Month Performance14.58%-2.67%2.82%3.74%
1 Year Performance13.64%-6.32%28.41%58.02%

Diaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXRX
Diaceutics
N/AGBX 137.50
flat
GBX 175
+27.3%
+12.9%£116.04M£26.08M-40.78151High Trading Volume
AGL
ANGLE
1.729 of 5 stars
GBX 5.60
-2.7%
GBX 40
+614.9%
-60.0%£18.03M£2.44M-0.83650Gap Down
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6.55
+0.7%
N/A-33.2%£12.67M£3.84M-15.9184High Trading Volume
PRM
Proteome Sciences
N/AGBX 2.80
-7.9%
N/A-24.1%£8.27M£10.88B-2.03240Gap Down
GDR
genedrive
N/AGBX 1.15
-2.1%
N/A-67.6%£6.53M£1.50M-0.3243Gap Down
GENI
GENinCode
N/AGBX 1.50
-6.3%
N/A-76.6%£2.66M£2.67M-0.442,300Gap Down
VRCI
Verici Dx
N/AGBX 0.55
+4.8%
N/A-92.7%£1.67M£5.91M-0.3219Gap Down
High Trading Volume
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLAI
LungLife AI
N/AGBX 3.50
-17.6%
N/A-73.1%£1.16M£33.87K-0.2815Gap Down
High Trading Volume
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-25.0015Gap Down
High Trading Volume

Related Companies and Tools


This page (LON:DXRX) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners